Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunesis Pharmaceuticals
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body) and identifying potential biomarkers.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cytologically or histologically confirmed chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or multiple myeloma (MM).
Evidence of relapsed disease
Measurable disease
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
You may not be if
Prior treatment with SNS-032 injection (previously known as BMS-387032)
Pregnant or breastfeeding
Unwilling to use an approved, effective means of contraception according to the study site's standards
Use of therapeutic anticoagulation agents
Prior allogeneic bone marrow transplantation
Prior chemotherapy, monoclonal antibodies, investigational agents, or radiation therapy within 21 days before the first dose; nitrosoureas and mitomycin are not permitted for at least 42 days before the first dose.
Prior pelvic radiation therapy or radiation to \> 25% of bone marrow reserve
Any other medical, psychological, or social condition that would contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
